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 ABSTRACT 
Carbamazepine, an anti-epileptic pharmaceutical agent commonly found in 
wastewater, is highly recalcitrant to standard wastewater treatment practices. This 
study investigated the mixture toxicity of carbamazepine transformation products 
formed during UV photolysis using three standard ecotoxicity assays (representing 
bacteria, algae and crustaceans). UV-treatment of 6 mg L
-1 
carbamazepine solution 
was carried out over a 120 min period and samples were removed periodically over 
the course of the experiment. Quantification results confirmed the degradation of 
carbamazepine throughout the treatment period, together with concurrent increases in 
acridine and acridone concentrations. Ecotoxicity was shown to increase in parallel 
with carbamazepine degradation indicating that the mixture of degradation products 
formed was more toxic than the parent compound. In fact, ecotoxicity was still greater 
than 60 % for all three endpoints even when the carbamazepine concentration had 
decreased to < 1 % of the starting concentration, and acridine and acridone had 
decreased to < 10 % of their maximum measured concentrations. Single compound 
toxicity testing also confirmed the higher toxicity of measured degradation products 
relative to the parent compound. These results show that transformation products 
considerably more toxic than carbamazepine itself are likely to be produced during 
UV treatment of wastewater effluents and/or photo-induced degradation of 
carbamazepine in natural waters. This study highlights the need to consider mixture 
toxicity and the formation and persistence of toxicologically relevant transformation 
products when assessing the environmental risks posed by pharmaceutical compounds. 
 
KEYWORDS 
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INTRODUCTION 
There are large knowledge gaps concerning the environmental fate and effects of most 
active pharmaceutical ingredients (APIs). For regulators, this translates to a high 
degree of uncertainty about the risks associated with pharmaceutically derived 
contaminants in the environment (Kümmerer, 2009a, 2009b). The quantities of APIs 
released to the environment may be relatively low in comparison with other types of 
pollutants such as pesticides and industrial pollutants, but there is a tendency for their 
environmental release to be continuous (via wastewater effluents) and the potential 
for environmental accumulation and/or chronic ecotoxicity has thus been noted (e.g. 
Besse and Garric, 2008; Fent et al., 2006; Ferrari et al., 2003; Hernando et al., 2006; 
Escher et al., 2011).  
 
Carbamazepine, an antiepileptic pharmaceutical compound and mood stabilising drug, 
has attracted particular attention in recent years due to its widespread detection in 
municipal wastewaters (e.g. Ternes, 1998; Ollers et al., 2001, Falås et al., 2012), 
surface waters (e.g. Ternes, 1998, Metcalfe et al., 2003; Andreozzi et al., 2003), and 
drinking waters (e.g. Stackelberg et al., 2004, 2007; Togola and Budzinski, 2008; 
Heberer et al., 2004). It is also noted to be highly resistant to biodegradation and thus 
highly recalcitrant under standard biological wastewater treatment conditions (Clara 
et al., 2005; Kosjek et al., 2009, Falås et al., 2012). Under these circumstances, 
advanced oxidation processes (AOPs) may offer additional treatment value (von 
Gunten, 2003; Huber et al., 2005; Macova et al., 2010; Kosjek et al., 2011, Hey et al., 
2012; Keen et al., 2012), however complete oxidation and mineralisation is not 
always achievable and stable transformation products formed during AOPs may also 
pose environmental risks (Aguerra et al (2005). The stability and ecotoxicity of 
transformation products formed during treatment and environmental transport are of 
major importance when assessing the suitability of water treatment options and in 
determining environmental risks associated with APIs in the environment.  
 
This paper presents the results of research investigating the ecotoxicity of 
carbamazepine and two of its UV transformation products (Kosjek, 2007), acridine 
and 9(10H)-acridone. In addition to single compound testing of these compounds 
using three different standard test organisms (bacteria, algae, and crustacean), an 
experiment was also conducted to investigate the changes in ecotoxicity occurring 
during UV treatment of water spiked with 6 mg L
-1
 carbamazepine. This experiment, 
conducted using a bench-top circulating flow UV-reactor system, was designed to 
compare the ecotoxicity of the initial carbamazepine-spiked solution with that of 
samples collected during the treatment process. These samples contained mixtures of 
carbamazepine and its UV-transformation products.  
 
This investigation into the relative toxicity of carbamazepine and its 
phototransformation products is relevant to future discussions regarding the treatment, 
control and fate of carbamazepine and carbamazepine-derived contaminants in the 
environment. Knowledge about carbamazepine’s UV-induced degradation pathway is 
also of interest from the perspective of sunlight-induced photochemical oxidation, as 
this may be a significant process controlling the gradual ongoing breakdown of 
carbamazepine released to receiving waters and natural aquatic environments. Indeed, 
for non biodegradable, non-sorbing APIs such as carbamazepine, sun-induced 
photodegradation may be the most important long-term process affecting persistence 
and toxicity in the environment.  
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This study provides an example of the ‘effect-driven approach’ for determining the 
risks associated with pollutant transformation products. The ‘effect driven approach’, 
described by Escher and Fenner (2011) in their paper on advances in environmental 
risk assessment of transformation products, focuses on ecotoxicity testing of reaction 
mixtures in which a parent compound is undergoing degradation (e.g. during UV-
treatment). This approach facilitates prioritisation of APIs and their transformation 
products for risk assessment purposes without requiring the prior identification and 
quantification of individual transformation products. In ‘effect driven’ assessments, 
compounds are prioritised for transformation product identification and further study 
if the reaction mixture increases in toxicity in parallel with decreasing parent 
compound concentration. 
 
1. METHODS 
2.1 Standards, Solvents, and Other Chemicals.  
Carbamazepine (99%, CAS 298-46-4) and N-Methyl-N- [tert-butyldimethyl-
silyl]trifluoroacetimide (MTBSTFA) were purchased from Acros Organics. Acridine 
(97%, CAS 260-94-6) and 9(10H)-acridone (99%, CAS 578-95-0) were obtained 
from Sigma-Aldrich.  
 
2.2 Chemical analyses 
Solid phase extraction (SPE) was used for sample preparation for all chemical 
analyses. Concentrated solutions (i.e. stock solutions and selected concentration check 
samples from the acute toxicity test dilution series) were initially diluted as 
appropriate (dilution factors ranged from 17 to 600) before loading at neutral pH onto 
Oasis
®
 HLB reversed-phase sorbent SPE cartridges (Waters, Corp., Milford, MA, 
USA). These cartridges were also used for preconcentration of the 150 mL 
subsamples taken throughout the carbamazepine UV-treatment experiment. SPE 
cartridges were conditioned with 3 mL of ethyl acetate, 3 mL methanol, and 3 mL of 
tap water. Sample aliquots were loaded on the SPE columns at a flow-rate of 4–5 mL 
min
−1
. Each cartridge was then washed with water (3 mL), dried for 30 min under 
vacuum and eluted with 1 mL acetone, 1 mL of 7/3 ethyl acetate / acetone mixture 
and 1 mL of ethyl acetate. The combined eluant was evaporated to dryness under a 
gentle nitrogen stream and reconstituted with 0.5 mL ethyl acetate.  
 
Acridone and carbamazepine were transformed into the tert-butyldimethyl-silyl ether 
derivatives by adding 30 μL MTBSTFA and maintaining the samples at 60°C for 12 
hours. A Varian 3800 gas chromatograph (GC) interfaced with an ion trap Saturn 
2000 mass spectrometer (MS) was used for analysis. 10 μL samples were injected 
(split-splitless) using a PTV injector at 80 °C for 0.30 min before being increased by 
200°C/min to 300°C and held for 5 min. A Zebron ZB-5 HT INFERNO 30 m × 0.25 
mm × 0.25 μm (Phenomenex) column was used for separation. The GC oven 
temperature programme was originally held at 80°C for 1 min, then increased by 
25°C/min to 225°C and held for 1 min; increased by 1°C/min to 231°C; increased by 
10°C/min to 280°C; increased by 45°C/min to 320°C and held at 320°C for a further 3 
min. The total runtime was 22.59 min. The mass analyser was operated in electron 
ionisation (EI) mode, and the following fragment ions were monitored for 
quantitation: m/z 179 for acridine, and m/z 252 and m/z 193 for the acridone-MTBS 
and carbamazepine-MTBS derivatives respectively.  
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For each sample, two parallel subsamples were extracted, derivatised and analysed 
according to the above protocol. Furthermore, each of these subsamples was injected 
and analysed twice, with the mean value taken as the relevant concentration. Method 
performance analyses showed satisfactory linearity (r
2
 > 0.98) and good repeatability 
for all three analytes. Blank control samples were also prepared and analysed. 
 
2.3 Ecotoxicity testing 
Three internationally standardised aquatic ecotoxicity tests (Table 1) were used to 
investigate the ecotoxicity of carbamazepine, acridine, and acridone. All 
measurements were conducted in triplicate. The selected ecotoxicity tests used 
organisms from different trophic levels and included the following short-term toxicity 
tests: 
 inhibition of bioluminescence in the marine bacterium Vibrio fischeri (Biotox 
testing kit; ISO 11348-3, 1998);  
 growth inhibition of the green algae Pseudokirchneriella subcapitata (ISO 8692, 
2004);  
 immobilisation of the crustacean Daphnia magna Straus (Cladocera, Crustacea) 
(ISO 6341, 1996).  
 
Table 1: Summary of experimental conditions for bacteria, algae, and daphnia 
ecotoxicity assays  
 
 Bacteria Algae Cladoceran 
Test species 
Vibrio fischeri 
(Photobacterium 
phosphoreum) 
Pseudokirchneriella 
subcapitata 
(Selenastrum 
capricornatum) 
Daphnia magna 
Temperature (°C) 15 20 20 
Optimal pH 7.0 ± 0.2 7.8 ± 0.2 8 ± 0.3 
Light source - 
Light intensity of 
10,000 lux supplied by 
cool white fluorescent 
tubes 
Darkness 
Media volume 200 µl/ vial 4 ml/ vial 50 ml/ vial 
Number of  
organisms 
exposed 
Variable 5-10·10
3
 cells/ml 
5 juvenile Daphnia per 
beaker 
Aeration 
Test vial is left 
uncovered during the 
test 
Constant air exchange 
through a hole in the lid 
of each growth vial 
Limited aeration 
(beakers are covered by 
a watch glass during the 
test) 
Test duration 30 min 48h 48h 
Replicates 3 - 6 3 - 6 2 - 3 
Assessment 
endpoint 
Inhibition of 
bioluminescence  
Biomass growth Daphnia immobilisation 
Measurement 
endpoint 
Luminescence 
Chlorophyll 
fluorescence 
Number of immobilised 
daphnia 
International 
Standard 
Organisation 
(ISO) Reference 
ISO 11348-3, 1998  ISO 8692, 2004  ISO 6341, 1996  
  
6 
 
For the Biotox test, 950 µL of sample solution and 50 µL of V. fischeri culture were 
mixed and bioluminescence was measured after 5, 15 and 30 minutes exposure to the 
test solution. Algal biomasses were determined using acetone pigment extractions as 
described by Mayer et al., (1997). For all three ecotoxicity tests, range finding tests 
were initially conducted for each compound and test species, prior to definitive tests 
combining ecotoxicity testing and test compound quantification. The aim was to 
obtain Effective Concentration values (i.e. EC10 and EC50) for each individual 
compound. In cases where complete inhibition/immobilisation of the test 
organism/endpoint did not occur within the solubility limits of the test compound, the 
assay was re-run with six replicates and LOEC/NOEC values were determined.  
 
The same three assays were also used to monitor changes in ecotoxicity during UV 
treatment of the 6 mg L
-1
 carbamazepine solution. All bioassays were conducted 
under static conditions with no renewal of the test solution. Dissolved oxygen and pH 
were measured at the beginning and end of the testing period to check compliance 
with standard test conditions. Quality control tests with potassium dichromate were 
also performed for all organisms. Furthermore, in addition to standard control samples, 
DMSO carrier controls were also included. 
 
2.4 Preparation of solutions for ecotoxicity testing 
Stock solutions for ecotoxicity testing of individual compounds were prepared in 
dimethylsulphoxide (DMSO). An aliquot of each stock solution was then diluted in 
ultra-pure water (MilliQ) to prepare the top concentration for ecotoxicity testing and 
further diluted using the appropriate growth medium to prepare the full concentration 
series for each test. The highest concentrations of solvent in the test solutions were 
always < 0.1 % of the total volume of test solution. The stock solution for the 6 mg L
-
1
 carbamazepine UV-treatment test was prepared in methanol. The concentration of 
methanol in the starting solution was 0.1 %. 
 
2.5 UV treatment of carbamazepine and related ecotoxicity assessments 
UV treatment of a 6 mg L
-1
 carbamazepine solution (prepared with MilliQ water) was 
conducted using a bench scale UV photoreactor with a circulating flow system. This 
experiment was carried out in triplicate. The apparatus consisted of a steel container 
(8 L), a waterpump (85 L h
-1
), and a medium pressure metal-halogen UV lamp (690 
W). The UV lamp (Bau 42, Scan Research A/S, Denmark) emitted a polychromatic 
light (λ = 185-400 nm) with enhanced emission in the relevant range for 
photochemical treatment (i.e. 190-250 nm). The emission spectrum for this lamp has 
been previously reported (Kosjek et al., 2009).  
 
The fate and behaviour of carbamazepine and its transformation products were 
studied over a 120 min irradiation period. A stock solution of 60 mg carbamazepine in 
10 mL of methanol was prepared and gradually added to 10 L of MilliQ water to give 
a 6 mg L
-1
 carbamazepine solution. This was allowed to circulate through the flow 
system for 10 minutes prior to the beginning of the test in order to allow for thorough 
mixing of the test solution. The first 150 mL sample (Time 0) was then taken. 
Subsequent samples were removed after 2, 5, 10, 15, 20, 25, 30, 45, 60, 90, and 120 
minutes of UV exposure. For each sampling event the lamp was switched off 
following the predetermined exposure period and the system left to circulate for a 
further 5 minutes before sampling. The temperature of the test solution increased 
during treatment, however ice was used to blanket the UV treatment system to 
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maintain the temperature below 50 °C at all times in order to limit thermal 
degradation. Carbamazepine, acridine and acridone concentrations were quantified 
throughout the UV treatment process using the SPE and GC-MS method described 
above. All samples were stored at 4 ºC prior to chemical and ecotoxicological 
analyses. 
 
2.6 Dose-response calculations and other statistical analyses 
Dose-response data for the V. fischeri bioassays were fitted using a log–logistic 
distribution, and EC10, EC50 values and their 95 % confidence intervals were 
calculated according to the method of Barnes et al. (2003). For the P. subcapitata 
bioassays, algal growth rate was calculated from the logarithmic increase in cell 
density in each individual algae culture, assuming exponential growth during the 48-h 
duration of the assay. Algal data analysis, including calculation of probit and Weibull 
dose–response models,  EC50 and EC10 values and their 95 % conﬁdence intervals was 
carried out using a Windows-based dose–response regression tool programmed by 
K.O.Kusk which functions according to the method described in Christensen et al., 
(2009). D. magna bioassay results were analysed using the Toxicity Data Analysis 
and Database Software (Toxcalc
TM
 v5.031), which generates median effective 
concentrations and their 95% confidence intervals and probit values. All other 
statistics presented in this paper were calculated using Microsoft Office Excel. 
 
2. RESULTS 
3.1 Ecotoxicity of carbamazepine, acridine and acridone 
Acute toxicity data for the individual compounds, expressed either as median 
effective concentrations (EC10/EC50) or NOECs and LOECs are presented in Table 2. 
The results of all three acute toxicity assays showed the parent compound, 
carbamazepine, to be significantly less toxic than either of the tested transformation 
products. Furthermore, of the two transformation products tested, acridone was 
consistently less toxic than acridine across all three assays. Table 3 presents a 
comprehensive list of acute/short-term toxicity results for aquatic based bioassays that 
have previously appeared in the literature for these three compounds. As a whole 
these values support the results presented above. 
 
Table 2: Ecotoxicity testing results for carbamazepine, acridine and acridone (all values in mg 
l
-1
). Results are based on measured solution concentrations. 
 
Ecotoxicity Assay Carbamazepine Acridine Acridone 
Bacteria, Vibrio fischeri  
(5, 15, 30 min) 
NOEC = 5.59 
LOEC = 8.16 
EC10 = 0.78 – 0.98 
EC50 = 5.34 - 6.90 
NOEC = 0.99 - 2.10 
LOEC = 1.44 - 3.07 
Algae, Pseudokirchneriella 
subcapitata (48 h) 
EC10 = 39 
 
EC10 = 0.11 
EC50 = 0.61  
EC10 = 0.87 
 
Cladoceran, Daphnia 
magna (48 h) 
EC10 > 30  
 
EC10 = 0.39 
EC50 = 0.71 
EC10 = 0.82 
EC50 = 1.49 
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Table 3: Published acute toxicity testing for carbamazepine, acridine, and acridone. The table 
includes a range of different aquatic species as well as results for benthic invertebrates. 
EC50/LC50 values relate either to solution concentrations or porewater concentrations as 
relevant to the particular test. All vales are given in mg L
-1
. 
 
Organism, test duration, and 
ecotoxicological endpoint 
Carbamazepine 
EC50/LC50  
Acridine  
EC50/LC50 
Acridone 
EC50/LC50 
Bacteria (Vibrio fischeri); 15 min; 
bioluminescence (Kim et al., 2007) 
52.2 
 
  
Bacteria (Vibrio fischeri); 30 min; 
bioluminescence (Ferrari et al., 
2003) 
> 81 
 
  
Bacteria (Vibrio fischeri); 5, 15, 30 
min; bioluminescence (Jos et al., 
2003) 
64 -  79    
Algae (Chlorella vulgaris); 48 h; 
growth inhibition (Jos et al., 2003) 
37  
 
  
Cladoceran (Daphnia magna); 48 h; 
immobilisation (Kim et al., 2007) 
>100  
 
  
Cladoceran (Daphnia magna); 48 h; 
immobilisation (Ferrari et al., 2003) 
> 13.8 
 
  
Cladoceran (Daphnia magna); 48 h; 
immobilisation (Jos et al., 2003) 
98    
Cladoceran (Daphnia spp.); 48 h; 
immobilisation (Cleuvers, 2002) 
> 100 
 
  
Cladoceran (Ceriodaphnia dubia); 
48 h; immobilisation (Ferrari et al., 
2003) 
77.7 
 
  
Cnidarian (Hydra attenuata); 96 h; 
tulip phase morphology; (Quinn et 
al., 2008) 
29.4  
 
  
Bivalve, Zebra mussel (Dreissena 
polymorpha); 96 h; cell cytoxicity; 
haemocytes, gill and digestive gland 
cells; (Parolini et al., 2011) 
5.1 – 6.8   
Algae (Desmodesmus subspicatus); 
24 h; growth inhibition (Eisentraeger 
et al., 2008) 
 2.1  
 
 
Algae spp. (7 species tested); 96 h; 
growth inhibition (Dijkman et al., 
1997) 
 0.08 – 0.79   
Cladoceran (Daphnia magna); 48 h; 
immobilisation (Eisentraeger et al., 
2008) 
 4.6  
 
 
Cladoceran (Daphnia pulex); 48 h; 
mortality (first instar) (Parkhurst et 
al., 1981) 
 2.3 
 
 
Cladoceran (Daphnia pulex); 28 d; 
reproduction (adult) (Parkhurst et al., 
1981) 
 0.8 
 
 
Cladoceran (Daphnia pulex); 24 h; 
immobilisation (adult) (Southworth 
et al., 1978) 
 1.71  
 
 
Benthic invertebrate, midge  0.07   
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(Chironomus riparius); 96 h; 
survival (first instar larvae) (Bleeker 
et al., 1998) 
 
Bivalve, Zebra mussel (Dreissena 
polymorpha); 48 h; filtration rate 
(Kraak et al., 1997) 
 0.96  
 
 
Calonoid copepod (Diaptomus 
clavipes); 14 h; mortality (first 
naupliar) (Cooney and Gehrs, 1984) 
 1.55  
 
 
Benthic invertebrate, midge 
(Chironomus riparius); 28 d; 
survival (emergence) (Paumen et al., 
2008)  
 0.37  
 
1.02 
 
Benthic invertebrate, midge 
(Chironomus riparius); 96h; survival 
(first instar larvae Bleeker et al 
(1999).  
 0.40 > 4.8 
Benthic oligochaete (Chironomus 
riparius); 28 d; mortality (Paumen et 
al., 2009) 
 0.25  
 
0.75 
 
Benthic oligochaete (Lumbriculus 
variegatus); 28 d; reproduction 
(Paumen et al., 2009) 
 0.23  
 
0.1  
 
 
 
3.2 Carbamazepine UV treatment experiment 
UV-treatment of 6 mg L
-1 
carbamazepine solution was carried out over a 120 min 
period and samples were removed periodically over the course of the experiment for 
ecotoxicity testing. The starting concentration of 6 mg L
-1
 is higher than measured 
environmental concentrations (Lacey et al., (2012), but facilitated the collection of 
measureable toxicity data from beginning to end of the UV-treatment experiment, 
even though the concentration of carbamazepine had reached < 1 % of the starting 
concentration by the end of the experiment.  Quantification results confirmed the 
degradation of carbamazepine throughout the treatment period, together with 
concurrent increases in acridine and acridone (Figure 1). Toxicity was shown to 
increase in parallel with these changes, indicating that the mixture of transformation 
products formed was more toxic than the parent compound by itself (Figures 2, S1, 
and S2; Table S1).  
 
Figure 1 shows the results of chemical quantification analyses performed on duplicate 
samples taken during one of the 6 mg L
-1 
carbamazepine UV-treatment tests. The 
concentration of carbamazepine decreased steadily during the UV exposure 
experiment (i.e. tenfold decrease in concentration within the first 60 min exposure), 
but was still detectable after 120 minutes. Quantifiable transformation products (i.e. 
those with commercially available standards) reached a peak level after about 15 
minutes exposure and then decreased. Concentration profiles of the two 
transformation products were both below the detection limit after 120 minutes of UV 
treatment. Although methanol, a potential radical scavenger, was used as the solvent 
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Figure 1. Measured concentrations of carbamazepine, acridine, and acridone in 
samples removed periodically from a 6 mg L
-1 
carbamazepine UV-treatment 
experiment. Measurements were carried out in duplicate and both results are plotted. 
0.00001
0.00010
0.00100
0.01000
0.10000
1.00000
10.00000
0 20 40 60 80 100 120 140
C
o
n
c
e
n
tr
a
ti
o
n
 i
n
 s
o
lu
ti
o
n
 (
m
g
/L
)
UV exposure time (mins)
Carbamazepine
Acridine
Acridone
 
 
Figure 2. Measured toxic response of Vibrio fischeri (inhibition in bioluminescence, 
15 min), Pseudokirchneriella subcapitata (growth inhibition, 48 h), and Daphnia 
magna (immobilisation, 48 h) exposed to solutions sampled from triplicate runs of the 
6 mg L
-1
 carbamazepine UV-treatment experiment. Error bars represent the standard 
error of the mean. 
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for the carbamazepine stock solution, Kosjek et al. (2009) showed that the 
concentration of methanol used in this experiment should not have inhibited the decay 
of carbamazepine or the identified transformation products during treatment. Their 
investigation used the same benchtop UV-treatment system as the current experiment 
and showed no significant difference in carbamazepine decay in the presence of 1.2, 
2.5 and 6.2 % methanol. As the experimental design for the study reported in this 
paper included only 0.1 % methanol by volume, the presence of methanol is not 
believed to have affected the chemical analysis results obtained.  
 
The pH of the carbamazepine UV test solution decreased during treatment from ~ pH 
5.8 to pH 3.6. Therefore, it was necessary to amend all samples to a standardised pH 
prior to toxicity testing in order to prevent pH-induced toxic responses (i.e. hydrogen 
ion toxicity) from confounding the ecotoxicity results. Samples were therefore 
amended to the appropriate pH range for each test organism (i.e. ~ pH 7 for V. fischeri; 
pH 7.8 for D. magna; pH 8 for P. subcapitata). Figure 2 summarises key results from 
the three ecotoxicity bioassays, and full results for all three organisms are given in 
Figures S1, S2 and Table S1. The results indicate increasing toxicity over time during 
UV-treatment in parallel with the formation of carbamazepine degradation products. 
Peak toxicity to V. fischeri occurred around 25 minutes after the onset of UV-
treatment when concentrations of acridine and acridone were also at their peaks, 
however the inhibition of V. fischeri bioluminescence remained around 70 % for the 
remainder of the experimental period, indicating that other transformation products 
must also be contributing to the ongoing toxic effect. This is also supported by the 
results of the P. subcapitata bioassay presented in Figure S2. In this case growth 
inhibition reached almost 100 % within 20 minutes of the onset of UV treatment, and 
greater than 100 % growth inihibition (i.e. cell death) was recorded in subsequent 
samples. By contrast, D. magna was less sensitive to the mixture toxicity of the UV 
treated carbamazepine solution (Figure 2; Table S1). This bioassay only demonstrated 
a measurable toxic effect (i.e. immobilisation of the organisms) after 45 minutes of 
UV treatment, but in keeping with the other bioassays this effect was still evident at 
the end of the experiment, indicating that toxic transformation products still remained 
in the solution at the end of the treatment period. 
 
3. DISCUSSION 
The presented results clearly indicate that the photodegradation products, acridine and 
acridone, are considerably more toxic than the parent compound carbamazepine 
across multiple trophic levels. Although the sensitivities of the different test 
organisms differed, all species showed greater toxicity of the tested photodegradation 
products compared with the parent compound carbamazepine and this result was 
further reflected in the increasing toxicity of the carbamazepine spiked water 
throughout the UV treatment experiment. This is the first time that these compounds 
have been tested simultaneously under the same experimental conditions and using 
the same suite of assays, however we note that the results compared favourably with 
existing acute toxicity data (Table 3).  
 
Recent efforts to quantify concentrations of carbamazepine in surface waters suggest 
that current environmental levels are well below the concentrations likely to cause 
acute toxicity to aquatic organisms. For instance, Lacey et al., (2012) referenced ten 
different studies measuring carbamazepine concentrations in wastewater influents and 
effluents across Europe and the USA, and reported a maximum effluent concentration 
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across those studies of 6.5 µg L
-1
. This is three orders of magnitude smaller than the 
lowest carbamazepine effect concentration measured in this experiment (V. fischeri, 
LOEC 8.16 mg L
-1
). However, studies which have investigated chronic/sublethal 
impacts of pharmaceutical compounds, including carbamazepine, have typically 
observed physiological effects at much lower contaminant concentrations than the 
measured threshold concentrations for acute toxicity. For example, Lurling et al., 
(2006) conducted chronic ecotoxicity tests using Daphnia pulex and observed 
significantly reduced rates of population growth at carbamazepine concentrations of 
200 µg L
-1
 due to retardation of juvenile somatic growth and subsequent delays in 
maturation and time to first reproduction. Similarly, Ferrari et al., (2003) reported 
carbamazepine NOEC and LOEC values of 25 µg L
-1
 and 100 µg L
-1
 respectively for 
a chronic 7-day test using reproduction of Ceriodaphnia dubia as the endpoint. These 
studies show that chronic carbamazepine exposure effects may occur at 
concentrations at least 3 orders of magnitude lower than the EC50 typically reported 
for acute Daphnia assays (e.g. this paper; Cleuvers, 2002; Jos et al., 2003; Kim et al., 
2007), and indicate that, based on estimates of ‘predicted no effect concentrations’ 
and ‘predicted environmental concentrations’ (Ferrari et al., 2003), carbamazepine 
poses a potential risk to aquatic environments. Given the current findings regarding 
the comparative ecotoxicities of carbamazepine and its UV-degradation products, this 
risk could actually be considerably greater than was previously supposed. 
 
As stated previously, carbamazepine is continually released to the environment at low 
concentrations due to its ubiquitous presence in wastewater effluents. It is assumed 
that removal of carbamazepine from surface waters will occur largely via the 
photodegradation pathway as sorption of carbamazepine is very limited (Ternes et al., 
2002; Scheytt et al., 2005; Clara et al., 2004) and it is resistant to biodegradation 
(Clara et al., 2004; Kosjek et al., 2009). Hence, the formation of stable 
photodegradation products is not only relevant to wastewater treatment processes, 
where UV treatment may be implemented to assist with microbial disinfection (e.g. 
inactivation of Cryptosporidium); it is also relevant to the breakdown of 
carbamazepine in natural river environments. With this in mind it is important to note 
the recalcitrance of the degradation products formed during this experiment. Even 
though progressive mineralisation could not be monitored by means of TOC analysis 
due to the presence of methanol in the spiking solution, the persistent toxicity at the 
end of the UV-treatment experiment provides evidence that complete mineralisation 
did not occur. Previous research (Kosjek et al., 2009) has shown that at least six 
photochemical derivatives are likely to form during the UV degradation of 
carbamazepine. It should also be noted that Li et al., (2011) reported that 
oxycarbazepine, a keto analogue of carbamazepine which is increasingly used as a 
substitute, also degrades to form essentially the same suite of UV-degradation 
products as carbamazepine. These authors also reported a toxic response in D. magna 
upon exposure to UV-treated oxycarbazepine solutions. By contrast, Rizzo et al., 
(2009) observed decreasing toxicity when 5 mg/L carbamazepine solution was treated 
by TiO2 photocatalysis, but it should be noted that the degradation pathway under that 
treatment regime (see Calza et al., 2012) would be different to the uncatalysed 
photolysis pathway relevant in this experiment.  
 
The UV dose applied in the current experiment is higher than that typically used for 
UV disinfection of water. A typical disinfection dose is equivalent to the UV dose 
delivered in less than 1 minute in the current experimental setup. Hence, even though 
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some degradation products may begin to form during UV-disinfection (note that toxic 
effects were observed in samples taken only 2 min after the onset of UV treatment) 
UV-disinfection doses are unlikely to significantly degrade carbamazepine. By 
contrast, if UV were to be purposely used as an end of pipe of treatment to photolyse 
chemicals the UV dose would be much higher, although not necessarily high enough 
to remove all toxic degradation products within a feasible timeframe. The feasibility 
of applying the UV lamp used in this study for degradation of both carbamazepine 
and other pharmaceuticals and estrogenic chemicals was evaluated in previous studies 
(Hansen et al., 2007a; Hansen et al., 2007b). Recalculating the doses from that study 
to the current laboratory setup indicates that 90 % removal of steroid estrogens would 
be equivalent to 2-5 min treatment (Hansen et al., 2007a), whereas some 
pharmaceuticals would require the equivalent of 20-40 min UV treatment to be 
degraded by 90 % (Hansen et al., 2007b).  
 
In this study, mixture toxicity was still high (> 60 % toxicity for all endpoints) at the 
end of the UV-treatment experiment (Figure 2), even though carbamazepine 
degradation had reached > 99 % and acridine and acridone concentrations had 
declined to < 10 % of their peak concentrations. These results highlight the need to 
further consider the identity, stability, and environmental relevance of recalcitrant 
carbamazepine degradation products. Researchers have already noted that other 
pharmaceuticals, such as prednisone (DellaGreca et al., 2003) and diclofenac 
(Schulze et al., 2010), may also form transformation products more toxic than the 
parent compound. Failing to account for toxicologically relevant transformation 
products can easily lead to substances being incorrectly identified as posing negligible 
environmental risks, when in fact they are significant. However, systematic 
ecotoxicity testing of treatment transformation products is complicated by the 
complexity of the relevant degradation pathways and the large numbers of 
intermediate compounds of varying stability which can be formed (e.g. Agüera et al., 
2005; Kosjek et al., 2009; Calza et al., 2012; Li et al., 2012). Moreover, degradation 
pathways may differ depending on the particular wastewater treatment regime or 
natural degradation pathway in question (e.g. activated sludge treatment or advanced 
oxidation vs. sunlight induced photodegradation). It is unrealistic to expect that all 
relevant compounds can be tested using conventional toxicity testing of individual 
compounds at multiple trophic levels, especially as the majority of these substances 
may not be commercially available. Identification, synthesis and isolation of such 
compounds is extremely time consuming, making experiments such as this, where 
mixture toxicity of the degradation products together as a whole is assessed, 
particularly useful for identifying cases where degradation pathway toxicity may be 
an issue. Further information on effect-driven approaches for assessing the 
toxicological relevance of transformation products can be found in Escher and 
Fenner’s critical review (2011). 
 
4. CONCLUSION  
The results of this study indicate that degradation products considerably more toxic 
than carbamazepine itself are likely to be produced as a result of UV treatment of 
wastewater effluents and/or photo-induced degradation of carbamazepine in natural 
waters. These findings are clearly relevant to ongoing debates regarding the potential 
environmental effects of pharmaceutically-derived compounds in the environment, 
highlighting the need to consider mixture toxicity and the formation and persistence 
of toxicologically relevant degradation products when assessing environmental risk.  
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SUPPLEMENTARY MATERIAL 
Table S1: Published acute toxicity testing for carbamazepine, acridine, and acridone. The 
table includes a range of different aquatic species as well as results for benthic invertebrates. 
EC50/LC50 values relate either to solution concentrations or porewater concentrations as 
relevant to the particular test. All vales are given in mg L
-1
. 
Organism, test duration, and 
ecotoxicological endpoint 
Carbamazepine 
EC50/LC50  
Acridine  
EC50/LC50 
Acridone 
EC50/LC50 
Bacteria (Vibrio fischeri); 15 min; 
bioluminescence (Kim et al., 2007) 
52.2 
 
  
Bacteria (Vibrio fischeri); 30 min; 
bioluminescence (Ferrari et al., 
2003) 
> 81 
 
  
Bacteria (Vibrio fischeri); 5, 15, 30 
min; bioluminescence (Jos et al., 
2003) 
64 -  79    
Algae (Chlorella vulgaris); 48 h; 
growth inhibition (Jos et al., 2003) 
37  
 
  
Cladoceran (Daphnia magna); 48 h; 
immobilisation (Kim et al., 2007) 
>100  
 
  
Cladoceran (Daphnia magna); 48 h; 
immobilisation (Ferrari et al., 2003) 
> 13.8 
 
  
Cladoceran (Daphnia magna); 48 h; 
immobilisation (Jos et al., 2003) 
98    
Cladoceran (Daphnia spp.); 48 h; 
immobilisation (Cleuvers, 2002) 
> 100 
 
  
Cladoceran (Ceriodaphnia dubia); 
48 h; immobilisation (Ferrari et al., 
2003) 
77.7 
 
  
Cnidarian (Hydra attenuata); 96 h; 
tulip phase morphology; (Quinn et 
al., 2008) 
29.4  
 
  
Bivalve, Zebra mussel (Dreissena 
polymorpha); 96 h; cell cytoxicity; 
haemocytes, gill and digestive gland 
cells; (Parolini et al., 2011) 
5.1 – 6.8   
Algae (Desmodesmus subspicatus); 
24 h; growth inhibition (Eisentraeger 
et al., 2008) 
 2.1  
 
 
Algae spp. (7 species tested); 96 h; 
growth inhibition (Dijkman et al., 
1997) 
 0.08 – 0.79   
Cladoceran (Daphnia magna); 48 h; 
immobilisation (Eisentraeger et al., 
2008) 
 4.6  
 
 
Cladoceran (Daphnia pulex); 48 h; 
mortality (first instar) (Parkhurst et 
al., 1981) 
 2.3 
 
 
Cladoceran (Daphnia pulex); 28 d; 
reproduction (adult) (Parkhurst et al., 
1981) 
 0.8 
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Cladoceran (Daphnia pulex); 24 h; 
immobilisation (adult) (Southworth 
et al., 1978) 
 1.71  
 
 
Benthic invertebrate, midge 
(Chironomus riparius); 96 h; 
survival (first instar larvae) (Bleeker 
et al., 1998) 
 0.07  
 
 
Bivalve, Zebra mussel (Dreissena 
polymorpha); 48 h; filtration rate 
(Kraak et al., 1997) 
 0.96  
 
 
Calonoid copepod (Diaptomus 
clavipes); 14 h; mortality (first 
naupliar) (Cooney and Gehrs, 1984) 
 1.55  
 
 
Benthic invertebrate, midge 
(Chironomus riparius); 28 d; 
survival (emergence) (Paumen et al., 
2008)  
 0.37  
 
1.02 
 
Benthic invertebrate, midge 
(Chironomus riparius); 96h; survival 
(first instar larvae Bleeker et al 
(1999).  
 0.40 > 4.8 
Benthic oligochaete (Chironomus 
riparius); 28 d; mortality (Paumen et 
al., 2009) 
 0.25  
 
0.75 
 
Benthic oligochaete (Lumbriculus 
variegatus); 28 d; reproduction 
(Paumen et al., 2009) 
 0.23  
 
0.1  
 
 
 
 
Table S2. Mean immobility of Daphnia magna exposed to solutions sampled from the 
6 mg L
-1
 carbamazepine UV-treatment experiments. Standard errors are given in 
brackets. 
 
Treatment Time 
(min) 
Mean immobility 
after 24 h 
exposure (%) 
Mean immobility 
after 48 h 
exposure (%) 
0 0 (0.0) 0 (0.0) 
2 0 (0.0) 0 (0.0) 
5 0 (0.0) 0 (0.0) 
10 0 (0.0) 0 (0.0) 
15 0 (0.0) 0 (0.0) 
20 0 (0.0) 0 (0.0) 
25 0 (0.0) 0 (0.0) 
30 0 (0.0) 0 (0.0) 
45 0 (0.0) 7 (0.7) 
60 11 (0.9) 17 (1.6) 
90 17 (1.2) 87 (1.1) 
120 49 (1.4) 100 (0.0) 
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Figure S1. Mean inhibition in bioluminescence of Vibrio fischeri exposed to solutions 
sampled from triplicate runs of the 6 mg L
-1
 carbamazepine UV-treatment experiment. 
Bioluminescence was measured after 5, 15 and 30 minutes exposure to the sample 
solutions. Error bars represent the standard error of the mean. 
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Figure S2. Mean inhibition in growth rate of Pseudokirchneriella subcapitata exposed 
to solutions sampled from the 6 mg L
-1
 carbamazepine UV-treatment experiment. Cell 
density was measured after 0, 24 and 48 h exposure to the sample solutions and the 
mean of three replicate samples is presented for each exposure time. Error bars 
represent the standard error of the mean. 
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